U.S., Dec. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07304427) titled 'Alwide Plus China Post-market Clinical Investigation' on Dec. 01.
Brief Summary: This is a prospective, single-arm, multi-center, post-market registry study conducted in China. The purpose is to evaluate the safety and effectiveness of the AlwideTM Plus balloon catheter for pre-dilatation of the aortic valve during TAVR in the real-world setting.
Study Start Date: Jan. 03
Study Type: OBSERVATIONAL
Condition:
Severe Aortic Stenosis
Transcatheter Aortic Valve Replacemen
Recruitment Status: COMPLETED
Sponsor: Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Published by HT Digital Content Services with permission from Health Dail...